Regeneron Pharmaceuticals, Inc.Viés de alta
REGN trend reversal and 30% upside
Recently, REGN has been in a downtrend. As supported by the technical indicators, there seems to be a potential trend reversal with a potential upside of 30% as evidenced by the oversold RSI level of <30 and a potential bullish divergence. A LONG initiated at or near $460 PS supported by near fib retracement level indicates 30% upside with the upside target of $600 and downside bearish target of $398 over the next quarter.
The technicals are also supported fundamentally by strong revenue growth of 30% Y/Y and a P/E of ~15 which is abnormally low for the stock. With the strong projected growth and multiple upcoming catalysts for the stock, it poses a unique opportunity for both mid-term and long-term investors. Furthermore, analyst consensus converges to mid $700.
REGN has been in a downtrend. As supported by the technical indicators, there seems to be a potential trend reversal with a potential upside of 30% as evidenced by the oversold RSI level of <30 and a potential bullish divergence. A LONG initiated at or near $460 PS supported by near fib retracement level indicates 30% upside with the upside target of $600 and downside bearish target of $398 over the next quarter.The technicals are also supported fundamentally by strong revenue growth of 30% Y/Y and a P/E of ~15 which is abnormally low for the stock. With the strong projected growth and multiple upcoming catalysts for the stock, it poses a unique opportunity for both mid-term and long-term investors. Furthermore, analyst consensus converges to mid $700.
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.